References
- Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US Claims Databases. Mayo Clin Proc 2006;81:1013–22
- McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
- Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–8
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3–12
- Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023–31 [Epub ahead of print 17 Feb 2007]
- Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2007 [available at http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1524–4733.2007.00213.x]
- Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105–16
- Cramer JA, Sunyecz JA, Derman R, et al. Women treated with monthly ibandronate improved persistence vs weekly bisphosphonates. Value Health 2007;10:A98 [poster P016]
- Cramer JA, Silverman S, Cziraky MJ, et al. Women are more persistent with monthly ibandronate vs weekly bisphosphonates: results from a retrospective database. Value Health 2007;10:A98 [poster P017]
- Zhang Q, Sautner Z, Shuvayu S. Real life persistency with Fosamax once weekly, Actonel once weekly, and Boniva once monthly among post-menopausal women in the USA. J Bone Min Res 2006;21(Suppl 1):S183 [poster SA 364]
- Weiss TW, von Allmen H, Henderson SC, et al. Persistency rates across weekly and monthly bisphosphonates: results from the IMS Health Longitudinal Prescription Database. J Bone Min Res 2006;21(Suppl 1):S182 [poster SA 358]
- Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opinion 2006;22:2383–91
- Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:42–5
- van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006;22:1757–64
- Cramer JA, Lynch NO, Gaudin A-F, et al. The impact of dosing frequency on compliance and persistence with bisphosphonate therapy: a comparison of the USA, UK and France. Clin Therapeutics 2006;28:1686–94
- Brankin E, Walker M, Lynch NO, et al. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249–56
- Briesacher BA, Andrade S, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Arth Rheum 2006 [poster Am Col Rheum]
- Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Int Med 1997;127:757–63
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: develop ment and validation. J Chron Dis 1987;40:373–83
- Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61
- Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253–59
- Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003;14:808–13
- Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165: 2414–9
- Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922–8
- Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922–8
- Lynch NO, Walker M, Cowell W, et al. An international comparison of dosing frequency on adherence with bisphosphonate therapy among postmenopausal women in the UK and Germany. J Bone Min Res 2005;21(Suppl 1)S180